Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.270
+0.010 (0.23%)
Mar 20, 2026, 10:55 AM EDT - Market open
Nuvation Bio Employees
Nuvation Bio had 298 employees as of December 31, 2025. The number of employees increased by 78 or 35.45% compared to the previous year.
Employees
298
Change (1Y)
78
Growth (1Y)
35.45%
Revenue / Employee
$211,081
Profits / Employee
-$686,668
Market Cap
1.48B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 298 | 78 | 35.45% |
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Dec 31, 2021 | 64 | 28 | 77.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Nurix Therapeutics | 317 |
| Harmony Biosciences Holdings | 293 |
| Pharvaris | 118 |
| Nanobiotix | 103 |
| Sionna Therapeutics | 59 |
NUVB News
- 2 days ago - Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 - PRNewsWire
- 13 days ago - Nuvation Bio Inc. (NUVB) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 16 days ago - Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 17 days ago - Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - PRNewsWire
- 22 days ago - Nuvation Bio to Participate in Upcoming Investor Conferences - PRNewsWire
- 4 weeks ago - Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026 - PRNewsWire
- 5 weeks ago - Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma - Business Wire